Investment Banking Weekly Scorecard - 1 March 2013

This provides an overview of the week in M&A, capital markets and syndicated loans, with league tables, up-to-date industry and country trends, as well as top transactions for the past week. Full details can be found in the attached report below, but headlines follow:

Investment Banking Weekly Scorecard - 1 March 2013

WW M&A Up 11% YTD

Worldwide M&A activity totaled $352 billion during the first two months of this year, an 11% increase compared to the first two months of 2012 and the strongest start for global deal making in two years. February M&A activity totaled $219.3 billion, up 65% from January, bolstered by deals for Heinz, Virgin Media, Dell and NBC Universal. The first two weeks of February accounted for 67% of monthly volume, which fell 58% during the last two weeks of the month. In the United States, deals announced during the second half of the month fell 85% from the opening two weeks.

JP Morgan currently leads the year-to-date rankings for worldwide M&A financial advisory with $134.4 billion. Goldman Sachs is firmly in second place with $102.9 billion, followed by Bank of America Merrill Lynch ($82.4 billion).

Pharma & Biotech Deal Making Doubles Over 2012

This week's $6.2 billion unsolicited bid for Ireland's Elan Corp PLC from Royalty Pharma Management and Mylan Inc's $1.9 billion acquisition of India's Agila Specialties Pvt Ltd brings the volume of deal making in the pharmaceutical and biotechnology sectors to $16.2 billion, more than double the level of activity last year at this time. This marks the strongest start for M&A in the sector since 2009 when Pfizer acquired Wyeth for $64.5 billion in January of that year. Targets in Ireland, the United States and India account for 87% of announced activity so far this year.

Morgan Stanley, which is advising Elan and Mylan, tops the ranking of financial advisors in the pharmaceutical and biotech sectors so far this year. Citi, which held the top spot during year-to-date 2012, follows closely behind in second place.

Global Investment Grade Corporate Debt Falls 23%

Global investment grade corporate debt totals $424.9 billion so far this year, a 23% decline from year-to-date 2012 and the slowest annual start for corporate debt issuance since 2010. Investment grade issuers in the Americas account for one-third of global activity and have seen a 22% increase compared to last year at this time. Asia Pacific and European issuers have registered year-over-year declines of 50% and 32%, respectively.

JP Morgan retains the top spot for global investment grade corporate debt underwriting with 7.8% market share, an increase of 0.5 market share points compared to last year. Bank of America Merrill Lynch, with an increase of 1.9 market share points compared to year-to-date 2012, moves into second place from fourth.

For more information throughout the week follow us on Twitter @Dealintel

Thomson Reuters

Please click below for this week’s Investment Banking Scorecard :

Jeudi 7 Mars 2013

Nouveau commentaire :

Articles and press releases are provided as is and have not been edited or checked for accuracy.
Any queries should be directed to the company issuing the press release or to the author issuing the article.
If you have a question for the author, or would like to comment on this article, use the box above. Your comment will be moderated before publication.
Your comment or question will appear below and the author or Finyear editor will be able to respond. Please note that your name will appear next to your comment (not your email).
Finyear does not offer financial advice of any kind and the opinions of authors are not necessarily those of Finyear.
By posting your comment, you agree to our acceptable use policy. If you read anything here that you consider inappropriate or offensive, please contact the adress : contact (at)
Finyear: Daily News & Best Practices for the Finance Executives (CFO, Treasurer, Controller, Credit manager, accountant, financial executive, etc...).

The Financial Year by Finyear. Copyright Finyear 2007-2013. You may share using our article tools.
Please don't cut articles from and redistribute by email or post to the web without permission: contact (at)

Les articles et les communiqués de presse sont fournis tels quels et n'ont pas été modifiés ou vérifiés.
Toute demande de renseignement doit être adressée à la société émettrice du communiqué de presse ou à l'auteur de l'article.
Si vous avez une question pour l'auteur, ou si vous désirez commenter cet article, utilisez la boîte ci-dessus. Votre commentaire sera modéré avant publication.
Votre commentaire ou question ci-dessous apparaîtra et l'auteur ou l'éditeur Finyear sera en mesure de répondre.
Veuillez noter, s'il vous plaît, que votre nom apparaîtra à côté de votre commentaire (pas votre adresse email).
Finyear n'offre pas de conseils financiers de quelque nature que ce soit et les opinions des auteurs ne sont pas nécessairement celles de Finyear.
En postant votre commentaire, vous acceptez notre politique d'utilisation et nos mentions légales.
Si vous lisez quelque chose ici que vous considérez inapproprié ou offensant, s'il vous plaît contacter l'adresse: contact (at)
Finyear: actus quotidiennes et meilleures pratiques pour les cadres financiers (CFO, trésorier, contrôleur, gestionnaire de crédit, comptable, cadre financier, etc ..).

The Financial Year by Finyear. Copyright Finyear 2007-2013. Vous devez utiliser nos outils de partage situés sur les articles.
SVP ne coupez-pas les articles issus de, ne les reroutez-pas par message sur le web sans autorisation : contact (at)

Les derniers articles publiés sur Finyear

Lettres Finyear


Magazine n°33

FY Research

Livres Blancs

  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30